<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02449291</url>
  </required_header>
  <id_info>
    <org_study_id>DP10018</org_study_id>
    <nct_id>NCT02449291</nct_id>
  </id_info>
  <brief_title>Study of APD421 as PONV Treatment (no Prior Prophylaxis)</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled Study of APD421 (Amisulpride for IV Injection) as Treatment of Established Post-operative Nausea and Vomiting, in Patients Who Have Had no Prior Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acacia Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acacia Pharma Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless,
      dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established
      PONV, in patients who have not had prior PONV prophylaxis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response (Success of Initial PONV Treatment)</measure>
    <time_frame>0-24 hours after treatment</time_frame>
    <description>The primary efficacy variable was the dichotomous variable: success or failure of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes* to 24 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 24-hour period after administration of study medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complete Response 0-2 Hrs</measure>
    <time_frame>0-2 hours after administration of study medication</time_frame>
    <description>Success of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes to 2 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 2-hour period after administration of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complete Response 2-24 Hrs</measure>
    <time_frame>2-24 hours after administration of study medication</time_frame>
    <description>Success of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) and no administration of anti-emetic rescue medication from 2 to 24 hours after administration of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>0-24 hours after study drug administration</time_frame>
    <description>Time to first violation of the criteria for complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Experiencing Incidence of Emesis</measure>
    <time_frame>30 mins to 24 hours after study drug administration</time_frame>
    <description>Number of patients experiencing vomiting or retching during the time period from 30 minutes to 24 hours after administration of study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Using Rescue Medication</measure>
    <time_frame>0-24 hours after study drug administration</time_frame>
    <description>Proportion of patients receiving pre-specified anti-emetic rescue medication at any time in the 24 hours post-treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Significant Nausea</measure>
    <time_frame>30 mins to 24 hours after study drug administration</time_frame>
    <description>Proportion of patients with nausea score ≥4 on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Nausea</measure>
    <time_frame>30 mins to 24 hours after study drug administration</time_frame>
    <description>Proportion of patients with nausea score ≥1 on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Severity of Nausea</measure>
    <time_frame>30 mins to 24 hours after study drug administration</time_frame>
    <description>Highest recorded nausea score on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution Score of Nausea (0-30 Mins)</measure>
    <time_frame>0-30 minutes after study drug administration</time_frame>
    <description>The evolution score of nausea was calculated as the area under the curve (AUC) of the nausea scores on a scale 0-10 (where 0 is no nausea and 10 is the worst nausea imaginable) obtained at four pre-planned time points: pre-dose (0-min), and 5, 15 and 30 minutes after administration of study medication, as well as any spontaneously reported episodes of nausea during the time period, plotted against time. A higher score represents a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">568</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>APD421 standard</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single (standard) dose IV APD421</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD421 high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single (high) dose IV APD421</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single IV placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APD421</intervention_name>
    <arm_group_label>APD421 high</arm_group_label>
    <arm_group_label>APD421 standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or female patients ≥ 18 years of age

          -  Provision of written informed consent

          -  Patients scheduled to undergo elective surgery (open or laparoscopic technique) under
             general anaesthesia (other than total intravenous anaesthesia with propofol) expected
             to last at least one hour from induction of anaesthesia to extubation

          -  Patients judged by the investigator to have a low to moderate risk of experiencing
             PONV. In forming this judgment, investigators should pay particular attention to risk
             factors such as a past history of PONV and/or motion sickness; habitual non-smoking
             status; female sex; and likely use of opioid analgesia post-operatively

          -  For females of child-bearing potential: ability and willingness to use a highly
             effective form of contraception (as defined in ICH M3 guidance, e.g., abstinence from
             sexual intercourse, surgical sterilisation (of subject or partner), combined oral
             contraceptive pill, a double-barrier method of contraception such as either an
             intra-uterine device (IUD) or an occlusive cap with spermicide, in conjunction with
             partner's use of a condom, or any other method or combination of methods with a
             failure rate generally considered to be &lt;1% per year) between the date of screening
             and at least 48 hours after administration of study drug

          -  In order to be eligible for randomisation, subjects must also:

             (i) have experienced a first episode of PONV not more than 24 hours after the end of
             their operation and prior to discharge from hospital (&quot;qualifying PONV episode&quot;), for
             which they have not already received any anti-emetic treatment; and (ii) not have
             received any agent likely to prevent or treat nausea or vomiting (given as prophylaxis
             or otherwise) in the period from 12 hours prior to the start of their operation up to
             the time of the qualifying PONV episode.

        Exclusion Criteria:

          -  Patients scheduled to undergo transplant surgery or any surgery where post-operative
             emesis may pose a significant danger to the patient

          -  Patients planned to receive only a local anaesthetic and/or regional neuraxial
             (intrathecal or epidural) block

          -  Patients who have received APD421 active ingredient for any indication within the last
             2 weeks

          -  Patients who are allergic to APD421 active ingredient or any of the excipients of
             APD421

          -  Patients with a significant, ongoing history of vestibular disease or dizziness

          -  Patients being treated with regular anti-emetic therapy (dosed at least three times
             per week), which is still ongoing within one week prior to surgery

          -  Patients with a known prolactin-dependent tumour (e.g. pituitary gland prolactinoma or
             breast cancer) or phaeochromocytoma

          -  Patients being treated with levodopa

          -  Patients who are pregnant or breast feeding

          -  Patients with documented or suspected alcohol or substance abuse within the past 6
             months

          -  Patients with a documented, clinically significant cardiac arrhythmia

          -  Patients diagnosed with Parkinson's disease

          -  Patients who have received emetogenic anti-cancer chemotherapy in the previous 4 weeks

          -  Patients with a history of epilepsy

          -  Any other concurrent disease or illness that, in the opinion of the investigator makes
             the patient unsuitable for the study

          -  Patients who have previously participated in this study or who have participated in
             another interventional clinical study involving pharmacological therapy within the
             previous 28 days (or longer exclusion period, if required by national or local
             regulations)

          -  Where local laws/regulations require: patients under legal protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Candiotti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 18, 2015</study_first_submitted>
  <study_first_submitted_qc>May 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2015</study_first_posted>
  <results_first_submitted>September 4, 2018</results_first_submitted>
  <results_first_submitted_qc>November 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 19, 2018</results_first_posted>
  <last_update_submitted>January 7, 2019</last_update_submitted>
  <last_update_submitted_qc>January 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>APD421 Standard</title>
          <description>Single (standard) dose IV APD421</description>
        </group>
        <group group_id="P2">
          <title>APD421 High</title>
          <description>Single (high) dose IV APD421</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Single IV placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="191"/>
                <participants group_id="P2" count="188"/>
                <participants group_id="P3" count="181"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="186"/>
                <participants group_id="P2" count="186"/>
                <participants group_id="P3" count="180"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>APD421 5mg</title>
          <description>APD421 5mg dose administered as a single, slow, intravenous (IV) push over about two minutes</description>
        </group>
        <group group_id="B2">
          <title>APD421 10mg</title>
          <description>APD421 10mg dose administered as a single, slow, intravenous (IV) push over about two minutes</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="191"/>
            <count group_id="B2" value="188"/>
            <count group_id="B3" value="181"/>
            <count group_id="B4" value="560"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.2" lower_limit="18" upper_limit="76"/>
                    <measurement group_id="B2" value="47.4" lower_limit="19" upper_limit="82"/>
                    <measurement group_id="B3" value="46.5" lower_limit="19" upper_limit="79"/>
                    <measurement group_id="B4" value="46.1" lower_limit="18" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="136"/>
                    <measurement group_id="B4" value="427"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="151"/>
                    <measurement group_id="B4" value="456"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Response (Success of Initial PONV Treatment)</title>
        <description>The primary efficacy variable was the dichotomous variable: success or failure of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes* to 24 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 24-hour period after administration of study medication.</description>
        <time_frame>0-24 hours after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg IV</title>
            <description>APD421 (amisulpride) at 5mg administered as a single, slow, intravenous (IV) push over about two minutes.</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg IV</title>
            <description>APD421 (amisulpride) at 10 mg administered as a single, slow, intravenous (IV) push over about two minutes.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Single IV placebo administered as a single, slow, intravenous (IV) push over about two minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response (Success of Initial PONV Treatment)</title>
          <description>The primary efficacy variable was the dichotomous variable: success or failure of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes* to 24 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 24-hour period after administration of study medication.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy analysis was a comparison of the incidence of the primary efficacy variable between the two groups that received APD421 and the group that received placebo, using Pearson’s χ2 test. The threshold for determining statistical significance in the comparison of incidence of success between the active and placebo groups (the primary efficacy analysis) was a p-value of 2.5% one-sided.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.016</p_value>
            <p_value_desc>One-sided p-value. After adjustment for multiplicity using Hommel's method. (Note: unadjusted p value = 0.016) A priori threshold for statistical significance = 0.025.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy analysis was a comparison of the incidence of the primary efficacy variable between the two groups that received APD421 and the group that received placebo, using Pearson’s χ2 test. The threshold for determining statistical significance in the comparison of incidence of success between the active and placebo groups (the primary efficacy analysis) was a p-value of 2.5% one-sided.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.016</p_value>
            <p_value_desc>One-sided p-value. After adjustment for multiplicity using Hommel's method. (Note: unadjusted p value = 0.015) A priori threshold for statistical significance = 0.025.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complete Response 0-2 Hrs</title>
        <description>Success of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes to 2 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 2-hour period after administration of study medication.</description>
        <time_frame>0-2 hours after administration of study medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg</title>
            <description>APD421 5mg dose administered as a single, slow, intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg</title>
            <description>APD421 10mg dose administered as a single, slow, intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Response 0-2 Hrs</title>
          <description>Success of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes to 2 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 2-hour period after administration of study medication.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="105"/>
                    <measurement group_id="O3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>One-sided p-value. No adjustment for multiple comparisons. A priori threshold for statistical significance = 0.025.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>One-sided p-value. No adjustment for multiple comparisons. A priori threshold for statistical significance = 0.025.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complete Response 2-24 Hrs</title>
        <description>Success of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) and no administration of anti-emetic rescue medication from 2 to 24 hours after administration of study medication.</description>
        <time_frame>2-24 hours after administration of study medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg</title>
            <description>APD421 5mg dose administered as a single, slow, intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg</title>
            <description>APD421 10mg dose administered as a single, slow, intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Response 2-24 Hrs</title>
          <description>Success of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) and no administration of anti-emetic rescue medication from 2 to 24 hours after administration of study medication.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="109"/>
                    <measurement group_id="O3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.170</p_value>
            <p_value_desc>One-sided p-value. No adjustment for multiple comparisons. A priori threshold for statistical significance = 0.025.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.552</p_value>
            <p_value_desc>One-sided p-value. No adjustment for multiple comparisons. A priori threshold for statistical significance = 0.025.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure</title>
        <description>Time to first violation of the criteria for complete response</description>
        <time_frame>0-24 hours after study drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg</title>
            <description>APD421 5mg dose administered as a single, slow, intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg</title>
            <description>APD421 10mg dose administered as a single, slow, intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure</title>
          <description>Time to first violation of the criteria for complete response</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159" lower_limit="68" upper_limit="NA">Treatment failure occurred in less than 75% of patients</measurement>
                    <measurement group_id="O2" value="177" lower_limit="53.5" upper_limit="NA">Treatment failure occurred in less than 75% of patients</measurement>
                    <measurement group_id="O3" value="79" lower_limit="34" upper_limit="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Regression, Cox</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Experiencing Incidence of Emesis</title>
        <description>Number of patients experiencing vomiting or retching during the time period from 30 minutes to 24 hours after administration of study medication</description>
        <time_frame>30 mins to 24 hours after study drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg</title>
            <description>APD421 5mg dose administered as a single, slow, intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg</title>
            <description>APD421 10mg dose administered as a single, slow, intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Experiencing Incidence of Emesis</title>
          <description>Number of patients experiencing vomiting or retching during the time period from 30 minutes to 24 hours after administration of study medication</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.209</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.440</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Using Rescue Medication</title>
        <description>Proportion of patients receiving pre-specified anti-emetic rescue medication at any time in the 24 hours post-treatment period</description>
        <time_frame>0-24 hours after study drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg</title>
            <description>APD421 5mg dose administered as a single, slow, intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg</title>
            <description>APD421 10mg dose administered as a single, slow, intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Using Rescue Medication</title>
          <description>Proportion of patients receiving pre-specified anti-emetic rescue medication at any time in the 24 hours post-treatment period</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Significant Nausea</title>
        <description>Proportion of patients with nausea score ≥4 on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.</description>
        <time_frame>30 mins to 24 hours after study drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg</title>
            <description>APD421 5mg dose administered as a single, slow, intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg</title>
            <description>APD421 10mg dose administered as a single, slow, intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Significant Nausea</title>
          <description>Proportion of patients with nausea score ≥4 on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.115</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.222</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Nausea</title>
        <description>Proportion of patients with nausea score ≥1 on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.</description>
        <time_frame>30 mins to 24 hours after study drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg</title>
            <description>APD421 5mg dose administered as a single, slow, intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg</title>
            <description>APD421 10mg dose administered as a single, slow, intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Nausea</title>
          <description>Proportion of patients with nausea score ≥1 on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="148"/>
                    <measurement group_id="O3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.474</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.505</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Severity of Nausea</title>
        <description>Highest recorded nausea score on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.</description>
        <time_frame>30 mins to 24 hours after study drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg</title>
            <description>APD421 5mg dose administered as a single, slow, intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg</title>
            <description>APD421 10mg dose administered as a single, slow, intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Severity of Nausea</title>
          <description>Highest recorded nausea score on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="3.24"/>
                    <measurement group_id="O2" value="4.2" spread="3.34"/>
                    <measurement group_id="O3" value="4.7" spread="3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.103</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.166</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evolution Score of Nausea (0-30 Mins)</title>
        <description>The evolution score of nausea was calculated as the area under the curve (AUC) of the nausea scores on a scale 0-10 (where 0 is no nausea and 10 is the worst nausea imaginable) obtained at four pre-planned time points: pre-dose (0-min), and 5, 15 and 30 minutes after administration of study medication, as well as any spontaneously reported episodes of nausea during the time period, plotted against time. A higher score represents a worse outcome.</description>
        <time_frame>0-30 minutes after study drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg</title>
            <description>APD421 5mg dose administered as a single, slow, intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg</title>
            <description>APD421 10mg dose administered as a single, slow, intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Evolution Score of Nausea (0-30 Mins)</title>
          <description>The evolution score of nausea was calculated as the area under the curve (AUC) of the nausea scores on a scale 0-10 (where 0 is no nausea and 10 is the worst nausea imaginable) obtained at four pre-planned time points: pre-dose (0-min), and 5, 15 and 30 minutes after administration of study medication, as well as any spontaneously reported episodes of nausea during the time period, plotted against time. A higher score represents a worse outcome.</description>
          <units>Score on a scale*min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1440.79" lower_limit="250.0" upper_limit="3450.0"/>
                    <measurement group_id="O2" value="1502.55" lower_limit="250.0" upper_limit="5375.0"/>
                    <measurement group_id="O3" value="1661.25" lower_limit="250.0" upper_limit="5812.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>APD421 5 mg</title>
          <description>Single 5 mg dose IV APD421</description>
        </group>
        <group group_id="E2">
          <title>APD421 10 mg</title>
          <description>Single 10 mg dose IV APD421</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Single IV placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gastrointestinal anastomotic leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="191"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="188"/>
                <counts group_id="E3" events="21" subjects_affected="21" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="191"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="188"/>
                <counts group_id="E3" events="22" subjects_affected="19" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="191"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="188"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="191"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="188"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no limitations or caveats associated with this study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gabriel Fox</name_or_title>
      <organization>Acacia Pharma Ltd</organization>
      <phone>01-223919764</phone>
      <email>gabrielfox@acaciapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

